ArriVent BioPharma (AVBP)
Market Price (12/27/2025): $21.92 | Market Cap: $918.7 MilSector: Health Care | Industry: Biotechnology
ArriVent BioPharma (AVBP)
Market Price (12/27/2025): $21.92Market Cap: $918.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% | Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -71% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.76, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -162 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% | ||
| Key risksAVBP key risks include [1] a heavy reliance on the successful clinical trial outcomes and regulatory approval of its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -33% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -36%, 3Y Excs Rtn is -71% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.76, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -162 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -21% |
| Key risksAVBP key risks include [1] a heavy reliance on the successful clinical trial outcomes and regulatory approval of its lead candidate, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Here are five key points that likely contributed to the 14.9% movement in ArriVent BioPharma (AVBP) stock during the approximate period from August 31, 2025, to December 27, 2025:
<br><br>
<b>1. Initiation of Global Pivotal Phase 3 ALPACCA Study:</b> On December 22, 2025, ArriVent BioPharma announced that the first patient had been dosed in its global pivotal Phase 3 ALPACCA study. This trial is evaluating firmonertinib monotherapy for the first-line treatment of EGFR PACC mutant non-small cell lung cancer (NSCLC), marking a significant clinical milestone aimed at supporting potential accelerated and full regulatory approvals for the company's lead drug candidate.
<br><br>
<b>2. Positive Phase 1b Firmonertinib Data Presentation:</b> The company presented the final analysis of positive firmonertinib monotherapy data from its global Phase 1b study in EGFR PACC mutant NSCLC at the 2025 World Conference on Lung Cancer on September 9, 2025. This presentation highlighted a median progression-free survival of 16.0 months and demonstrated significant central nervous system activity, providing encouraging results for the drug's potential.
<br><br>
<b>3. Strategic Commercial Leadership Appointment:</b> ArriVent BioPharma strengthened its leadership team with the appointment of Brent S. Rice as Chief Commercial Officer on September 22, 2025. This strategic hire, bringing over 25 years of experience in the biotechnology and pharmaceutical industry, signals the company's active preparation for the potential commercialization of firmonertinib.
<br><br>
<b>4. Favorable Analyst Endorsements and Price Targets:</b> Throughout late 2025, several Wall Street analysts initiated coverage or reiterated positive ratings for ArriVent BioPharma, accompanied by price targets significantly above the prevailing stock price. For instance, Truist Financial initiated coverage with a "buy" rating and a $43.00 target price in November 2025, and BTIG Research followed with a "buy" rating and a $45.00 price target in December 2025, reflecting growing confidence in the company's future.
<br><br>
<b>5. Robust Financial Position and Extended Cash Runway:</b> An analysis in December 2025 highlighted ArriVent BioPharma's strong financial health, reporting cash and equivalents of $305.4 million. This substantial cash position is projected to provide a runway until mid-2027, offering stability and supporting ongoing research, development, and commercialization efforts without immediate financing concerns.
Show moreStock Movement Drivers
Fundamental Drivers
The 21.9% change in AVBP stock from 9/26/2025 to 12/26/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 18.03 | 21.97 | 21.85% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 35.01 | 41.91 | -19.73% |
| Cumulative Contribution | � |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| AVBP | 21.9% | |
| Market (SPY) | 4.3% | 29.3% |
| Sector (XLV) | 15.2% | 23.9% |
Fundamental Drivers
The -4.1% change in AVBP stock from 6/27/2025 to 12/26/2025 was primarily driven by a -23.6% change in the company's Shares Outstanding (Mil).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 22.91 | 21.97 | -4.10% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 33.90 | 41.91 | -23.64% |
| Cumulative Contribution | � |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| AVBP | -4.1% | |
| Market (SPY) | 12.6% | 25.1% |
| Sector (XLV) | 17.0% | 27.5% |
Fundamental Drivers
The -20.3% change in AVBP stock from 12/26/2024 to 12/26/2025 was primarily driven by a -24.8% change in the company's Shares Outstanding (Mil).| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 27.58 | 21.97 | -20.34% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.00 | 0.00 | � |
| P/S Multiple | ∞ | ∞ | � |
| Shares Outstanding (Mil) | 33.58 | 41.91 | -24.81% |
| Cumulative Contribution | � |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| AVBP | -20.3% | |
| Market (SPY) | 15.8% | 31.3% |
| Sector (XLV) | 13.3% | 32.4% |
Fundamental Drivers
nullnull
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| AVBP | ||
| Market (SPY) | 48.0% | 26.1% |
| Sector (XLV) | 18.2% | 26.9% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AVBP Return | - | - | - | - | 33% | -16% | 11% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| AVBP Win Rate | - | - | - | - | 50% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| AVBP Max Drawdown | - | - | - | - | -24% | -39% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
AVBP has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -16.1% | -25.4% |
| % Gain to Breakeven | 19.1% | 34.1% |
| Time to Breakeven | 599 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.8% | -33.9% |
| % Gain to Breakeven | 40.4% | 51.3% |
| Time to Breakeven | 116 days | 148 days |
| 2018 Correction | ||
| % Loss | -15.8% | -19.8% |
| % Gain to Breakeven | 18.8% | 24.7% |
| Time to Breakeven | 326 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -40.6% | -56.8% |
| % Gain to Breakeven | 68.3% | 131.3% |
| Time to Breakeven | 1,100 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for ArriVent BioPharma (AVBP):- The Tesla of next-generation EGFR lung cancer drugs.
- The Genentech of precision oncology for lung cancer.
AI Analysis | Feedback
```html- Furmonertinib: An investigational oral, brain-penetrant, highly mutant-selective EGFR tyrosine kinase inhibitor (TKI) being developed for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
AI Analysis | Feedback
ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancers. As a clinical-stage company, it does not currently have any commercially approved products on the market.
Therefore, ArriVent BioPharma does not currently have "major customers" in the traditional sense of entities purchasing its products and generating product-related revenue.
However, once ArriVent BioPharma successfully develops and receives regulatory approval for its therapeutic products, its commercialization strategy would typically involve selling primarily to other companies in the healthcare supply chain. These would include:
- Pharmaceutical Wholesalers and Distributors: These companies purchase drugs directly from manufacturers and distribute them to hospitals, pharmacies, clinics, and other healthcare providers. Major players in this sector include:
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
- Hospitals and Integrated Delivery Networks: Large hospital systems and integrated networks often purchase medications through wholesalers but may also negotiate directly with manufacturers for certain high-volume or specialized products.
- Specialty Pharmacies: For highly specialized or rare disease drugs, specialty pharmacies are critical partners in distribution and patient management.
While the ultimate beneficiaries are individual patients, the direct "customers" in the sales channel for a biopharmaceutical manufacturer like ArriVent would be these corporate entities within the healthcare supply chain.
AI Analysis | Feedback
nullAI Analysis | Feedback
Zhengbin (Bing) Yao, PhD Chief Executive Officer
Dr. Bing Yao is a co-founder and the Chief Executive Officer and Chairman of ArriVent BioPharma. He has over 25 years of experience in the biotechnology and pharmaceutical industry. Dr. Yao co-founded Viela Bio in 2018, where he served as Chairman and CEO. Viela Bio was acquired by Horizon Therapeutics for $3.1 billion in 2021. Prior to Viela Bio, he was Senior Vice President, Head of Respiratory, Inflammation, Autoimmunity iMED at MedImmune, and Senior Vice President, Head of Immuno-Oncology Franchise at AstraZeneca. He also led the project team leaders group for immunology, neurosciences, virology, and metabolism at Genentech and was Vice President and Head of Research for Tanox before its acquisition by Genentech in 2007. Dr. Yao has held key roles at Aventis and Amgen. ArriVent's Series A financing was led by Hillhouse Capital Group.
Winston Kung, MBA Chief Financial Officer
Mr. Kung serves as the Chief Financial Officer and Treasurer of ArriVent BioPharma. From 2004 to 2007, he worked at Amgen Inc. as a co-founder of the Alliance Management group and as the deal lead on multiple acquisitions within the Corporate Development group. Before that, from 1999 to 2002, he was part of the Business and Corporate Development group at Genentech, Inc., which was later acquired by Roche Group in 2009.
Stuart Lutzker, MD, PhD President, R&D
Dr. Stuart Lutzker is a co-founder and the President of Research and Development at ArriVent BioPharma.
Robin LaChapelle, MA Chief Operating Officer
Ms. Robin LaChapelle is a co-founder and the Chief Operating Officer of ArriVent BioPharma.
Yang Wang, PhD Chief Technology Officer
Dr. Yang Wang is the Chief Technology Officer of ArriVent BioPharma. She has over 17 years of experience in biopharmaceutical process development and commercialization. Most recently, she was Senior Vice President, Head of Chemistry, Manufacturing and Controls at Viela Bio, overseeing process development, manufacturing, and supply. Previously, Dr. Wang was Senior Director, Analytical Sciences at Biopharmaceutical Development, MedImmune.
AI Analysis | Feedback
Key Risks to ArriVent BioPharma (AVBP)
ArriVent BioPharma, Inc. (AVBP) faces several significant risks inherent to the biotechnology industry, primarily centered around the successful development and commercialization of its product candidates.
- Clinical Trial and Regulatory Approval Risks: As a clinical-stage biopharmaceutical company, ArriVent's success is heavily reliant on the successful outcome of its clinical trials, particularly for its lead candidate, firmonertinib. There is an inherent risk of serious adverse effects, delays in clinical trials, or ultimately, a lack of regulatory approval from authorities like the FDA, which would significantly impact the company's future.
- Lack of Profitability and Capital Requirements: ArriVent is not yet profitable, exhibiting negative earnings per share and free cash flow deficits. The company requires substantial capital to fund its ongoing research and development activities. While it currently has a cash runway, there's a risk that it may need to raise additional capital if it does not achieve profitability, especially given its increasing cash burn.
- Competition: ArriVent's lead drug, firmonertinib, is being developed in a competitive landscape within the lung cancer treatment market. Several established pharmaceutical companies, such as Johnson & Johnson and Takeda, already have approved drugs or are developing treatments targeting similar mutations (e.g., EGFR exon 20 insertion mutations), posing a competitive threat.
AI Analysis | Feedback
nullAI Analysis | Feedback
The addressable market sizes for ArriVent BioPharma's main products or services are currently not explicitly detailed with specific financial figures in the provided search results. ArriVent BioPharma's lead product candidate is firmonertinib (also known as furmonertinib), an oral, mutation-selective epidermal growth factor receptor (EGFR) inhibitor. It is being evaluated for non-small cell lung cancer (NSCLC) patients with various EGFR mutations, including exon 20 insertion mutations and P-loop and alpha-c-helix compressing (PACC) mutations. While ArriVent BioPharma focuses on the oncology market, particularly lung cancer, and aims to address unmet medical needs in this area, the exact global or U.S. addressable market size for firmonertinib in its specific indications (EGFR exon 20 insertion mutations and PACC mutations in NSCLC) is not provided in a quantifiable monetary value within the search results. The company's forward-looking statements acknowledge "estimates of our addressable market", but these estimates are not disclosed. For context, a competitor's drug, AstraZeneca's Tagrisso, which is also an EGFR TKI for EGFR-mutated NSCLC, generated over $5.8 billion in global sales in 2023. ArriVent BioPharma is initially targeting the U.S. market for its cancer treatments. ArriVent BioPharma is also developing ARR-217, an antibody-drug conjugate (ADC) for gastrointestinal cancers, and ARR-002, another ADC for solid tumors. However, no addressable market sizes are identified for these pipeline products in the provided information.AI Analysis | Feedback
ArriVent BioPharma (AVBP) is a clinical-stage biopharmaceutical company with several key drivers expected to fuel its future revenue growth over the next two to three years:
- Commercialization of Firmonertinib for NSCLC with EGFR Exon 20 Insertion Mutations: The company's lead development candidate, firmonertinib, is in a global pivotal Phase 3 FURVENT study for the treatment of first-line non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Enrollment for this study has been completed, and top-line data is anticipated in early 2026. ArriVent holds exclusive development and commercialization rights for firmonertinib outside of Greater China. The recent appointment of a Chief Commercial Officer underscores the company's preparations for a potential market launch.
- Expansion of Firmonertinib into Additional NSCLC Indications: Beyond the primary indication, firmonertinib is also being evaluated in Phase 1b clinical trials for NSCLC patients with other activating EGFR mutations, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC. Successful advancement and approval in these additional indications would significantly broaden firmonertinib's market potential and contribute to revenue growth. Final analysis of firmonertinib monotherapy data in EGFR PACC mutant NSCLC from a global Phase 1b study was presented in September 2025.
- Advancement and Commercialization of ARR-217 for Gastrointestinal Cancers: ArriVent expanded its pipeline by acquiring exclusive global rights outside of Greater China to develop and commercialize ARR-217, a CDH17-targeted Antibody-Drug Conjugate (ADC) for the treatment of gastrointestinal cancers, through a collaboration with Lepu Biopharma. This program represents a new product in a different therapeutic area and a new modality, offering diversification of future revenue streams. The first Investigational New Drug (IND) application for ARR-217 was submitted in China in March 2025.
- Development of a Broader Antibody-Drug Conjugate (ADC) Pipeline: ArriVent has also established a multi-target ADC collaboration agreement with Alphamab Oncology to discover, develop, and commercialize novel ADCs for various oncology indications, with exclusive rights outside of Greater China for candidates like ARR-421 and ARR-173. Additionally, ARR-002 is in discovery for solid tumors. As these earlier-stage ADC programs progress through clinical development, they represent significant long-term revenue growth potential.
- Strategic Collaborations and Pipeline Expansion: ArriVent's strategy involves leveraging strategic collaborations to access innovative biopharmaceutical products and accelerate their global development. These partnerships, such as those with Lepu Biopharma and Alphamab, are crucial for expanding the company's oncology pipeline and its potential commercial reach, thereby driving future revenue generation. Analyst forecasts predict substantial revenue growth for ArriVent, with projections reaching $81.2 million in 2026 and $2.2 billion in 2027.
AI Analysis | Feedback
Share Issuance
- ArriVent BioPharma completed an Initial Public Offering (IPO) of 9,722,222 shares of common stock at $18.00 per share, which closed around January 30, 2024.
- In July 2025, the company priced a public offering, raising approximately $75 million in gross proceeds through the sale of 2,482,692 shares of common stock at $19.50 per share and pre-funded warrants to purchase up to 1,363,469 shares at $19.4999 per warrant.
- The company granted underwriters a 30-day option to purchase up to an additional 15% of the total securities offered in the July 2025 public offering.
Inbound Investments
- ArriVent has raised a total funding of $236 million over two rounds.
- The latest funding round was a Series B for $155 million on December 16, 2022, with General Catalyst and Sofinnova Investments leading 15 participating investors.
- Its first funding round occurred on June 9, 2021.
Outbound Investments
- ArriVent expanded its pipeline in Q1 2025 by acquiring ARR-217, a CDH17-targeted Antibody-Drug Conjugate (ADC) for gastrointestinal cancers, through a collaboration with Lepu Biopharma, which included a $40 million upfront payment.
- The company engages in strategic collaborations with industry leaders such as Aarvik Therapeutics and Shanghai Allist Pharmaceuticals to advance its pipeline.
Capital Expenditures
- The development of biopharmaceutical product candidates is capital-intensive, with expenses expected to increase substantially due to ongoing clinical trials for firmonertinib and other pipeline programs.
- Research and development expenses were $61.3 million for Q1 2025 and $89.0 million for the first six months of 2025, significantly higher than previous periods.
- As of June 30, 2025, ArriVent had $254.5 million in cash and investments, and with the $81.1 million raised in July 2025, they expect to fund operations to mid-2027, primarily focusing on advancing firmonertinib and other pipeline programs like ARR-217.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| ArriVent BioPharma Earnings Notes | ||
| ArriVent BioPharma (AVBP) Operating Cash Flow Comparison | Financials | |
| ArriVent BioPharma (AVBP) Net Income Comparison | Financials | |
| ArriVent BioPharma (AVBP) Operating Income Comparison | Financials | |
| ArriVent BioPharma (AVBP) Revenue Comparison | Financials |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to AVBP. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for ArriVent BioPharma
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.0% |
| Rev Chg 3Y Avg | 2.6% |
| Rev Chg Q | 9.1% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Price Behavior
| Market Price | $21.97 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 01/26/2024 | |
| Distance from 52W High | -24.9% | |
| 50 Days | 200 Days | |
| DMA Price | $20.99 | $20.36 |
| DMA Trend | down | up |
| Distance from DMA | 4.7% | 7.9% |
| 3M | 1YR | |
| Volatility | 56.7% | 52.7% |
| Downside Capture | 124.34 | 125.15 |
| Upside Capture | 194.75 | 84.25 |
| Correlation (SPY) | 30.4% | 31.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.10 | 1.35 | 1.32 | 1.28 | 0.86 | 0.19 |
| Up Beta | 3.46 | 3.01 | 3.42 | 1.70 | 0.77 | 0.24 |
| Down Beta | 3.07 | 0.42 | 0.22 | 0.20 | 0.68 | 0.05 |
| Up Capture | 223% | 227% | 169% | 148% | 78% | 14% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 12 | 24 | 35 | 65 | 121 | 231 |
| Down Capture | -98% | 72% | 93% | 164% | 115% | 72% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 6 | 16 | 26 | 57 | 123 | 224 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
nullBased On 5-Year Data
nullBased On 10-Year Data
nullEarnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2025 | 3.1% | 14.7% | 34.9% |
| 8/11/2025 | -3.3% | 8.6% | 10.2% |
| 5/12/2025 | -0.8% | -3.9% | 21.6% |
| 3/3/2025 | -6.7% | -7.4% | -21.7% |
| 11/14/2024 | -11.9% | -14.0% | -16.1% |
| 8/14/2024 | -0.4% | -0.1% | -0.8% |
| 3/28/2024 | 2.5% | 3.3% | -8.5% |
| SUMMARY STATS | |||
| # Positive | 2 | 3 | 3 |
| # Negative | 5 | 4 | 4 |
| Median Positive | 2.8% | 8.6% | 21.6% |
| Median Negative | -3.3% | -5.6% | -12.3% |
| Max Positive | 3.1% | 14.7% | 34.9% |
| Max Negative | -11.9% | -14.0% | -21.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11102025 | 10-Q 9/30/2025 |
| 6302025 | 8112025 | 10-Q 6/30/2025 |
| 3312025 | 5122025 | 10-Q 3/31/2025 |
| 12312024 | 3032025 | 10-K 12/31/2024 |
| 9302024 | 11142024 | 10-Q 9/30/2024 |
| 6302024 | 8142024 | 10-Q 6/30/2024 |
| 3312024 | 5082024 | 10-Q 3/31/2024 |
| 12312023 | 3282024 | 10-K 12/31/2023 |
| 6302023 | 10042023 | DRS/A 6/30/2023 |
| 12312022 | 1262024 | 424B4 12/31/2022 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.